These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8054617)

  • 1. [Hemostasis-regulating role of nicotinic acid and its analogs].
    Akhundov RA; Tret'iak VM; Khalilova EM; Sadykhov RV
    Biull Eksp Biol Med; 1993 Mar; 115(3):267-9. PubMed ID: 8054617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of neferine on platelet aggregation in rabbits].
    Yu J; Hu WS
    Yao Xue Xue Bao; 1997; 32(1):1-4. PubMed ID: 11243209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
    Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of acetylsalicyclic and nicotinic acids and complamin on the formation of a prostacyclin-like substance by the aortic wall].
    Lakin KM; Baluda VP; Lukoianova TI; Romanovskaia VN; Baluda MV
    Farmakol Toksikol; 1980; 43(5):581-5. PubMed ID: 7004908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of dikvertin on the cyclic nucleotide level in thrombocytes].
    Kubatiev AA; Iadigarova ZT; Rud'ko IA; Bykov VA; Tiukavkina NA
    Biull Eksp Biol Med; 1999 Sep; 128(9):267-9. PubMed ID: 10560042
    [No Abstract]   [Full Text] [Related]  

  • 6. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production.
    Lechi C; Andrioli G; Gaino S; Tommasoli R; Zuliani V; Ortolani R; Degan M; Benoni G; Bellavite P; Lechi A; Minuz P
    Thromb Haemost; 1996 Nov; 76(5):791-8. PubMed ID: 8950792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Stimulation of prostacyclin biosynthesis as a possible mechanism of action of dipyridamole (author's transl)].
    Mentz P; Pönicke K; Block HU; Giessler C; Blass KE; Bayer BL; Förster W
    Arzneimittelforschung; 1981; 31(12):2075-82. PubMed ID: 7037009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin.
    Vane JR; Moncada S
    Ciba Found Symp; 1980; 71():79-97. PubMed ID: 6245837
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
    Gordge MP; Hothersall JS; Noronha-Dutra AA
    Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage.
    Hsiao G; Lin KH; Chang Y; Chen TL; Tzu NH; Chou DS; Sheu JR
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1998-2004. PubMed ID: 15976325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathological changes in thrombocyte-vascular and coagulative hemostasis under the influence of lead chloride and their correction by using a synthetic analog of prostacyclin].
    Myslyts'kyĭ VF; Podolian SK
    Fiziol Zh (1994); 1999; 45(4):99-104. PubMed ID: 10474809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the dose range of 0.5-2.0 mg/kg, acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies.
    Vainio M; Mäenpää J; Riutta A; Ylitalo P; Ala-Fossi SL; Tuimala R
    Acta Obstet Gynecol Scand; 1999 Feb; 78(2):82-8. PubMed ID: 10023867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eicosanoids and venous thromboembolism.
    Fitzpatrick JW; Giudice JC; Papa L; Freed N
    J Am Osteopath Assoc; 1983 Dec; 83(4):301-6. PubMed ID: 6365860
    [No Abstract]   [Full Text] [Related]  

  • 15. [Problems of a pharmacologic search for inhibitors of platelet aggregation].
    Lakin KM
    Kardiologiia; 1988 Oct; 28(10):120-6. PubMed ID: 3066962
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism of anti-proliferative action of eicosapentaenoic acid (EPA) in vascular cell growth: its effect on signal transduction system.
    Terano T; Hirai A; Shiina T; Tamura Y; Saitoh Y
    Adv Exp Med Biol; 1997; 407():399-404. PubMed ID: 9321983
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet Dysfunction in Type 1 Diabetes: Stressing the Thromboxanes.
    Wisinski JA; Kimple ME
    Diabetes; 2016 Feb; 65(2):349-51. PubMed ID: 26798121
    [No Abstract]   [Full Text] [Related]  

  • 18. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimucytin: a collagen-like aggregating inducer isolated from Trimeresurus mucrosquamatus snake venom.
    Teng CM; Ko FN; Tsai IH; Hung ML; Huang TF
    Thromb Haemost; 1993 Mar; 69(3):286-92. PubMed ID: 8470053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies of phosphodiesterase inhibitors for cardiovascular disease.
    Numano F; Kishi Y; Ashikaga T
    Adv Second Messenger Phosphoprotein Res; 1992; 25():395-407. PubMed ID: 1313270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.